Amelia J Tesone
Overview
Explore the profile of Amelia J Tesone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Svoronos N, Perales-Puchalt A, Allegrezza M, Rutkowski M, Payne K, Tesone A, et al.
Cancer Discov
. 2016 Oct;
7(1):72-85.
PMID: 27694385
Significance: Ablating estrogenic activity delays malignant progression independently of the tumor cell responsiveness, owing to a decrease in the mobilization and immunosuppressive activity of MDSCs, which boosts T-cell-dependent antitumor immunity....
2.
Perales-Puchalt A, Svoronos N, Rutkowski M, Allegrezza M, Tesone A, Payne K, et al.
Clin Cancer Res
. 2016 Jul;
23(2):441-453.
PMID: 27435394
Purpose: To define the safety and effectiveness of T cells redirected against follicle-stimulating hormone receptor (FSHR)-expressing ovarian cancer cells. Experimental Design: FSHR expression was determined by Western blotting, immunohistochemistry, and...
3.
Allegrezza M, Rutkowski M, Stephen T, Svoronos N, Tesone A, Perales-Puchalt A, et al.
Cancer Res
. 2016 Mar;
76(9):2561-72.
PMID: 26980764
Many signal transduction inhibitors are being developed for cancer therapy target pathways that are also important for the proper function of antitumor lymphocytes, possibly weakening their therapeutic effects. Here we...
4.
Tesone A, Rutkowski M, Brencicova E, Svoronos N, Perales-Puchalt A, Stephen T, et al.
Cell Rep
. 2016 Feb;
14(7):1774-1786.
PMID: 26876172
Special AT-rich sequence-binding protein 1 (Satb1) governs genome-wide transcriptional programs. Using a conditional knockout mouse, we find that Satb1 is required for normal differentiation of conventional dendritic cells (DCs). Furthermore,...
5.
Rutkowski M, Stephen T, Svoronos N, Allegrezza M, Tesone A, Perales-Puchalt A, et al.
Cancer Cell
. 2014 Dec;
27(1):27-40.
PMID: 25533336
The dominant TLR5(R392X) polymorphism abrogates flagellin responses in >7% of humans. We report that TLR5-dependent commensal bacteria drive malignant progression at extramucosal locations by increasing systemic IL-6, which drives mobilization...
6.
Stephen T, Rutkowski M, Allegrezza M, Perales-Puchalt A, Tesone A, Svoronos N, et al.
Immunity
. 2014 Sep;
41(3):427-439.
PMID: 25238097
Tumor-reactive T cells become unresponsive in advanced tumors. Here we have characterized a common mechanism of T cell unresponsiveness in cancer driven by the upregulation of the transcription factor Forkhead...
7.
Rutkowski M, Allegrezza M, Svoronos N, Tesone A, Stephen T, Perales-Puchalt A, et al.
J Vis Exp
. 2014 Apr;
(85).
PMID: 24748051
Breast cancer is a heterogeneous disease involving complex cellular interactions between the developing tumor and immune system, eventually resulting in exponential tumor growth and metastasis to distal tissues and the...
8.
Tesone A, Svoronos N, Allegrezza M, Conejo-Garcia J
Front Immunol
. 2013 Dec;
4:435.
PMID: 24339824
A common characteristic of solid tumors is the pathological recruitment of immunosuppressive myeloid cells, which in certain tumors includes dendritic cells (DCs). DCs are of particular interest in the field...
9.
Cubillos-Ruiz J, Baird J, Tesone A, Rutkowski M, Scarlett U, Camposeco-Jacobs A, et al.
Cancer Res
. 2012 Feb;
72(7):1683-93.
PMID: 22307839
Modulating the activity of miRNAs provides opportunities for novel cancer interventions. However, low bioavailability and poor cellular uptake are major challenges for delivering miRNA mimetics specifically to tumor cells. Here,...
10.
Tesone A, Regueira E, Canosa L, Ceballos N
Gen Comp Endocrinol
. 2012 Jan;
176(3):500-6.
PMID: 22285601
The reduction of A-ring of glucocorticoids to produce 5α-dihydro-derivatives by 5α-reductases has been considered as a pathway of irreversible inactivation. However, 5α-reduced metabolites of corticosterone and testosterone have significant biological...